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Background: To evaluate intranasal administration of butorphanol on postoperative pain and early postoperative
cognitive dysfunction in old patients undergoing H-uvulopalatopharyngoplasty (H-UPPP).
Methods: A total of 260 male patients (65 to 77 years old) with obstructive sleep apnea hypopnea syndrome and
scheduled for H-UPPP were divided randomly to receive intranasal butorphanol, intravenous butorphanol, intranasal
fentanyl, or intravenous saline (controls). The definition of preemptive analgesia is that the tested drugs are given
before anesthesia induction. Visual analog scale (VAS) and Bruggrmann comfort scale (BCS) scores were recorded at
postoperative 1, 6, 12, 18, 24, 36, and 48 h. Postoperative cognitive dysfunction (POCD) was evaluated by Mini-Mental
State Examination (MMSE) scores assessed one day before, and 1, 3, and 7 days postsurgery.
Results: Compared with control group, those given preemptive analgesia required significantly less sufentanil during
surgery, had less pain at postoperative 6–12 h; those given butorphanol experienced less nausea and vomiting, less
pain at postoperative 6–24 h, and less POCD. Compared with patients given fentanyl, those given butorphanol
required significantly less postoperative fentanyl, had less pain at postoperative 18–24 h, less nausea and vomiting,
and less POCD. Compared with patients given intravenous butorphanol, those who received butorphanol by nasal
route required significantly less postoperative fentanyl, had less pain at 36 and 48 h, and less POCD.
Conclusion: Intranasal administration of butorphanol is safe and effective, reducing postoperative usage of
analgesics and the incidence of POCD in old patients undergoing H-UPPP.
Trial registration: ChiCTR-TRC-14004121.
Keywords: Butorphanol, Intranasal administration, Preemptive analgesia, H-UPPP, Early postoperative cognitive
dysfunctionBackground
Uvulopalatopharyngoplasty (H-UPPP) has been used in-
creasingly for the treatment of obstructive sleep apnea-
hypopnea syndrome (OSAHS). However, postoperative
throat pain can cause a strong stress response that im-
pairs the hippocampus, white matter, basal ganglia and
prefrontal cortex, ultimately leading to postoperative
cognitive dysfunction (POCD) [1-4]. In particular, elderly
patients are at high risk of POCD [5]. Therefore,* Correspondence: sundefengyl@163.com
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unless otherwise stated.appropriate analgesia is necessary to prevent the develop-
ment of POCD in elderly patients treated with H-UPPP.
Morphine and other opioid analgesics have been given
for postoperative pain, but their use is often accompan-
ied by nausea, vomiting, and other adverse reactions.
Butorphanol is a derivative of morphinan that induces
analgesia by activating the k-opioid receptor. It reduces
the incidence of nausea, vomiting, and other postopera-
tive side effects by partially antagonizing the -opioid re-
ceptor. The pain relieving effect of butorphanol is five
times greater than that of morphine, without obvious ac-
tivity on receptors [6,7]. Our previous study showed that
intravenous administration of butorphanol had good
analgesia effects on patients after H-UPPP [8]. Otherhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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butorphanol took only 20 min to achieve peak effect,
with high absolute bioavailability [9]. If analgesic drugs
have high absolute bioavailability, we expect decreased
consumption of analgesics and diminished adverse reac-
tion. By observing the effects of butorphanol via intrana-
sal and intravenous injection on both postoperative
analgesia and POCD, and comparing them with fentanyl
intranasal administration and normal saline intravenous
injection, we expected decreased consumption of analge-
sics, diminished adverse reaction and low incidence of
POCD in elderly patients with H-UPPP.
Aim of the study
The primary outcome is that intranasal administration
of butorphanol could lower the incidence of POCD in
old patients undergoing H-UPPP; therefore, the primary
endpoint is POCD assessment within one week after the
operation. Secondary outcome is that intranasal admin-




The Ethics Committee of First Affiliated Hospital of
Dalian Medical University approved this study. Patients
or their families provided a signed informed consent form.
This study was registered as ChiCTR-TRC-14004121. The
consort flow chart for randomized controlled trial (RCT)
was shown in Figure 1.Figure 1 The consort flow chart for RCT.A total of 260 male patients (aged 65 to 77 y) with
OSAHS who visited the first Affiliated Hospital of Dalian
Medical University hospital between 1 January 2010
and 30 August 2014 were selected to undergo H-
UPPP under general anesthesia. All patients weighed
88–111 kg, with BMI 28–35 kg/m2, apnea-hypopnea index
21–42 times/h, American Society of Anesthesiologists
(ASA) physical status grade I or II, and the Mallampati
airway classification grade I to IV based on the degree of
exposure with pharyngeal in patients.
Rapid intubation was performed in patients with the
Mallampati airway classification grades I or II, while
awake intubation was performed in patients with the
Mallampati airway classification grade III or IV. No
patient had a history of drug use, and all had a sim-
ple mental state examination score > 23, junior high
school or higher education, no significant history of
neurological disease or hyperthyroidism, no liver or
renal dysfunction, no severe visual or hearing impair-
ment, and no recent use of sedatives, anti-coagulants,
anti-depressants, or analgesics. Randomization was
carried out with a computer-generated random number
table. The allocations were concealed in consecutively
numbered, sealed envelopes. Patients were randomly
assigned into four groups (n = 65) based on the assign-
ment found in the numbered envelopes as follows:
intranasal administration of butorphanol (group A), intra-
venous administration of butorphanol (group B), intranasal
administration of fentanyl (group C) and control group
(group D).
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ous induction agent and quick acting muscle relaxants.
It could enable patients to reach the unconsciousness
and muscle paralysis in a short time to complete a tra-
cheal intubation. Awake intubation refers to the tracheal
intubation in patients with consciousness. The detailed
method of awake intubation was as following:
 Interpret to the patient properly, emphasizing
cooperative matters, such as relaxing muscles, keep
breathing, not to hold breath and not to feel nausea,
in order to help the patient cooperate fully.
 Apply 1% dicaine on throat tracheal surface
anesthesia for 1–2 minutes.
 To calm the patient, diminish throat reflection,
intravenous inject Innovar (haloperidol 5 mg
fentanyl 0.1 mg) by 1 ~ 2 ml for inducing.
 The technique should be as light as possible, carry
out the endotracheal intubation slowly and accurately.
Sample size
Sample size calculation was performed based on the pri-
mary endpoint of POCD incidence. We assume that
there is a 26% POCD incidence on control group and
3% on intranasal administration of butorphanol group.
The selected sample size was adjusted for multiple com-
parisons using the technique of Bonferroni for control-
ling the overall type I error rate at 5%. The adjusted
sample size of 63 patients per arm (totally 252 patients,
including 10% drop-out rate) will have a power of 80%
to detect difference between treatment arms, with a 2-
sided alpha = 0.5.
Anesthesia procedures
The patients had routine preoperative fasting for 8 h,
and light liquid for 2 h, without preoperative treatment.
Routine monitoring of bispectral index (BIS), blood
pressure, heart rate, blood oxygen saturation, and inva-
sive arterial pressure was performed during surgery.
Bispectral index was performed using an HXD-1
multifunctional monitor. Ten minutes before the induc-
tion of anesthesia, Group A received 2 mg nasal drip
butorphanol (Novo Yang, Jiangsu Hengrui Medicine),
Group B received 2 mg intravenous injection of butor-
phanol, group C received 0.1 mg nasal drip of fentanyl
0.1 mg (Yichang Humanwell Pharmaceutical), and group
D received 2 mL intravenous injection of saline.
For Mallampati I and II patients in four groups,
anesthesia was induced by intravenous injection of
0.05 mg/kg midazolam, 0.2 μg/kg sufentanil, 1 mg/kg
propofol, and 0.3 mg/kg cisatracurium. For Mallampati
III and IV patients in four groups, anesthesia was in-
duced by awake fiberoptic intubation with intravenous
injection of Innovar (haloperidol 5 mg fentanyl 0.1 mg)by 1–2 ml. After endotracheal intubation through the
nose, mechanical ventilation was performed at a respira-
tory rate of 8–12 times/min, inspiratory to expiratory
ratio 1:2, tidal volume 8–10 mL/kg, ventilation 100–
120 mL/kg/min, and oxygen concentration 60-70%. Dur-
ing the operation, the tidal volume was adjusted to
maintain an end-tidal carbon dioxide partial pressure of
35 mmHg (i.e., 4.65 kPa). For all patients in four groups,
anesthesia was maintained by continuously intravenous
injection of 0.2 μg/kg/h sufentanil, 0.15-0.30 mg/kg/h
cisatracurium, and 2–3 mg/kg/h propofol.
Blood pressure was maintained fluctuations in mean
arterial pressure to no more than 20% of base value by
continuously intravenous injection of nicardipine and
esmolol. The bispectral index was maintained between
50 and 60 by adjusting infusion speed of sufentanil and
propofol. Within 15 min of the end of surgery the infu-
sion of propofol was ended. The infusion of nicardipine
and esmolol was ended after extubation.
Immediately after surgery, patient-controlled intraven-
ous analgesia (PCIA) was administered using fentanyl,
and the patient was moved into post-anesthesia care unit
(PACU). Patients were extubated in PACU when the bis-
pectral index was more than 90, patients were fully
awake, muscle strength and oxygen saturation were the
same as before surgery, and secretions and blood were
cleaned from the mouth and throat.
Intranasal administration
Intranasal administration was performed as described pre-
viously [10]. Briefly, the butorphanol dilution was dropped
slowly into the side of the nose, to avoid going directly into
the throat. The nasal cavity was filled with the butorphanol
dilution and the patient remained in the original position
for 1 min to fully absorb the butorphanol.
Steward’s postanesthetic recovery scoring
Steward’s postanesthetic recovery scoring was performed
as described previously [11]. Specifically, scoring was
based on consciousness (awake, 2; responding to stimuli,
1; not responding, 0), airway (coughing on command or
crying, 2; maintaining good airway, 1; airway requires
maintenance 0), and movement (moving limbs purpose-
fully, 2; non-purposeful movements, 1; not moving, 0).
PCIA setting
Fentanyl as analgesics after surgery, a loading dose of
0.3 μ g / kg, background dose of 0.1 μ g.Kg−1.h−1, a single
dose of 0.1 μg/kg, lockout time 15 min, use time of 48 h.
Anesthesia monitoring
The operation time, PACU stay, and dosages of sufenta-
nil, propofol, and fentanyl were recorded. Examinations
were performed at postoperative 1, 6, 12, 18, 24, 36 and
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nausea, vomiting, pruritus, respiratory depression, dizzi-
ness, urinary retention, and other adverse reactions were
documented. The mini-mental state examination (MMSE)
scores were determined by psychiatrists one day before,
and one day, 3 days and 7 days after the operation.
Pain and comfort rating
Pain was rated using a visual analog scale (VAS) [12].
Comfort was rated using the Bruggrmann comfort scale
(BCS) [13]. The pain after surgery was scored as: 0, per-
sistent pain; 1, pain at rest; 2, no pain at rest but slight
pain when swallowing; 3, no pain when swallowing; 4,
no pain when the wounds were touched.
POCD assessment
The MMSE score evaluation criteria consisted of: orien-
tation, to time (5 points) and to place (5 points); mem-
ory, instant (3 points) and delayed (3 points); language
ability, naming (2 points), narration (1 point), and writing
(1 point); complex commands (5 points); and calculation
(5 points); with a possible total of 30 points. The subjects
were judged as having POCD when preoperative and post-
operative MMSE scores differed by 2 points or more [14].
Statistical analysis
Data are expressed as mean ± standard deviation and
were analyzed using SPSS 15.0 statistical software. In-
group were compared with analysis of variance for re-
peated measurement design. The differences between
groups were compared by analysis of a sheffe’s test, enu-
meration data were compared with the chi-squared test.
P < 0.05 was considered statistically significant.
Results
General characteristics of the patients
We found no significant differences in general condition,
operation time, or the amount of propofol used in theTable 1 Demographics, clinical features, and analgesics admin
A
Age (y) 74 ± 3
Weight (kg) 100 ± 11
ASA class (I/II) 35/30
Hypertension or coronary heart disease (%) 29
Pulmonary disease (%) 14
Operative time (min) 115 ± 15
PACU stay (min) 30 ± 6a
Sufentanil (μg) 64 ± 12a
Propofol (mg) 1379 ± 108
Postoperative fentanyl (g) 651 ± 65a,b,c
aCompared with group D, P = 0.041; bcompared with group B, P = 0.049; ccomparedfour groups (P > 0.05). Compared with group D, PACU
stay was shorter and the dosage of sufentanil was lower
in groups A, B, and C (P = 0.041). In addition, postoper-
ative dosage of fentanyl was significantly lower in group
A than in groups B, C, or D (P = 0.049, Table 1).
Postoperative pain
VAS scores were significantly decreased while BCS scores
were significantly increased in group A at T2-7, group B
at T2-5, and group C at T2-3, relative to the correspond-
ing time points in group D (P = 0.041, each). Compared
with group C at the corresponding time points, VAS
scores were decreased while BCS scores were increased
in group A at T4-7, and group B at T4-5 (P = 0.032).
Compared with group B, VAS scores were decreased
while BCS scores were increased in group A at T6-7
(P = 0.048, Figure 2).
Incidence of adverse reactions
Compared with group C and D, the incidence of nausea
and vomiting was reduced in groups A and B (P = 0.031).
However, the incidence of other adverse reactions showed
no significant difference among the four groups (P > 0.05,
Table 2).
MMSE score and the incidence of POCD
Compared with T1, the MMSE score was significantly
lower at T2 and T3 in groups B, C, and D (P = 0.041).
Moreover, at T2 and T3, the MMSE score was signifi-
cantly higher in group A and B than in group C and D,
and MMSE scores were significantly higher in group A
than in group B (P = 0.048, Table 3).
The incidence of POCD was 3.1%, 13.8%, 24.6%, and
26.2%, in groups A, B, C, and D, respectively. The inci-
dence of POCD was significantly lower in groups A and
B than in groups C and D, and it was significantly lower
in group A than in group B (P = 0.043).istered to the patients in the four groups
B C D
73 ± 4 72 ± 4 72 ± 5




116 ± 14 119 ± 13 120 ± 12
32 ± 4a 32 ± 5a 51 ± 9
65 ± 10a 66 ± 9a 98 ± 11
1382 ± 105 1377 ± 107 1381 ± 108
775 ± 76a,c 911 ± 101a 1232 ± 104
with group C, P = 0.047.
Figure 2 Scores of VAS (A) and BCS (B) in four groups. VAS scores were significantly decreased while BCS scores were significantly increased
in group A at T2-7, group B at T2-5, and group C at T2-3, relative to the corresponding time points in group D (P = 0.041, each). Compared with
group C at the corresponding time points, VAS scores were decreased while BCS scores were increased in group A at T4-7, and group B at T4-5
(P = 0.032). Compared with group B, VAS scores were decreased while BCS scores were increased in group A at T6-7 (P = 0.048).
Yang et al. BMC Anesthesiology 2015, 15:20 Page 5 of 7
http://www.biomedcentral.com/1471-2253/15/20Discussion
POCD indicates complications in the central nervous
system and occurs frequently in elderly patients. It usu-
ally manifests as decline of memory, attention, language
ability, and social interaction [15-17]. Age is one of the
most significant factors influencing the incidence of
POCD [5]. With increasing numbers of elderly patients
who undergo surgery, POCD is an important cause of
increased costs, prolonged hospitalization and recovery
time, and decline in quality of life [4,18].
Elderly patients often have hypertension, coronary
heart disease, diabetes, lung disease, chronic bronchitis,
and other age-related diseases and their metabolic func-
tion is poor. They thus have a significantly lower toler-
ance for surgery and anesthesia [19,20]. Laalou et al.
[21] reported that one week after surgery the incidence
of POCD was 23% in patients aged 60 to 69 years and
29% in patients over 70 years. Newman et al. [22] re-
ported that the incidence of POCD was 2 to 10 times
higher in patients aged over 65 years than in younger
patients, and three times higher in patients aged 75 years
than in patients aged 65–75 years. It is important to
identify the features of anesthesia that are associated
with this side effect in elderly patients.
VAS and BCS are common methods used in clinical
evaluation of the effects of postoperative analgesia, andTable 2 Comparison of postoperative adverse reactions







A 7.7a,b 0 0 12.3 0
B 9.2a,b 0 0 13.8 0
C 26.2 0 0 12.3 0
D 24.6 0 0 15.4 0
aCompared with group C, P = 0.029; bcompared with group D, P = 0.031.they have good specificity and reliability [12,13,23,24].
The MMSE method is commonly used in the evaluation
of cognitive function, may exclude the emotional re-
sponse to cognitive dysfunction, and is highly reliable
and easy to conduct [14]. By using these methods in the
present study we found that intranasal administration of
butorphanol achieved good analgesia, effectively sup-
pressed postoperative pain in elderly OSAHS patients
who underwent H-UPPP, reduced postoperative anal-
gesic dosage, and decreased the incidence of POCD. In-
tranasal administration of butorphanol was superior to
intravenous delivery of butorphanol and intranasal ad-
ministration of fentanyl.
Intranasal administration is a convenient, well-tolerated,
non-invasive transmucosal route of administration. The
nasal surface area is quite large, rich in submucosal vascu-
lature, highly intertwined with arteries, veins and capillar-
ies, and highly conducive to penetration and absorption of
the drug. After administration through the nose, the drug
can penetrate rapidly from the mucosa to blood cir-
culation, avoiding gastrointestinal metabolism, hepatic
degradation, and metabolism. In contrast, intravenous ad-
ministration does not have these advantages and often
causes nausea, vomiting, and other complications [25].
The better effects of intranasal administration of
butorphanol compared with that of intravenous adminis-
tration may be due to its higher absolute bioavailability.Table 3 Comparison of MMSE scores in the four groups
Group T1 T2 T3 T4
A 28.2 ± 1.5 27.7 ± 1.8a,b,c 27.7 ± 1.9a,b,c 27.7 ± 1.9
B 28.0 ± 1.3 25.5 ± 1.9b,c,d 25.6 ± 2.0b,c,d 27.7 ± 2.0
C 27.9 ± 1.5 23.5 ± 1.7d 23.1 ± 2.0d 27.7 ± 1.9
D 28.1 ± 1.4 23.3 ± 1.7d 23.2 ± 1.8d 27.6 ± 2.0
aCompared with group B, P = 0.048; bcompared with group C, P = 0.042.
ccompared with group D, P = 0.042; dcompared with T1, P = 0.041.
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ing were significantly lower in groups A and B than in
groups C and D. This may be related to the antagonism
of butorphanol to the-opiod receptor. At T2 and T3, the
mean MMSE scores were significantly higher in groups A
and B than in groups C and D, and significantly higher in
group A than in group B. The incidence of POCD was
significantly lower in groups A and B than in groups C
and D, and was significantly lower in group A than in
group B. These data indicate that both routes of adminis-
tration of butorphanol could reduce the incidence of
POCD, but intranasal administration of butorphanol is
superior to either intravenous administration of butor-
phanol or intranasal administration of fentanyl. This may
be mainly due to the inhibition of the postoperative stress
response, thereby reducing the incidence of aseptic
inflammation in the brain which leading to the hippo-
campus, anterior cerebral white matter,basal ganglia and
prefrontal cortex maintaining relatively good physio-
logical function because of complete absorption after in-
tranasal administration which produced high quality and
duration of postoperative analgesia, and another reason
for the lower incidence of POCD in group A is that the
dosage of postoperative analgesics was significantly lower
in group A than in the other three groups. In group C,
despite intranasal administration fentanyl was metabo-
lized faster than butorphanol. Thus the quality of anal-
gesia was significantly worse than in group A, leading to
higher incidence of POCD than in group A.
The limitations of this study are as follows: we focused
on old and obese patients. In addition, butorphanol is
used in an ORL minor procedure.
Conclusions
In summary, for elderly patients with OSAHS undergo-
ing H-UPPP, preemptive intranasal administration of
butorphanol effectively suppressed postoperative pain,
reduced the dosage of analgesics, and decreased the inci-
dence of POCD. Intranasal administration of butorpha-
nol was superior to vein administration of butorphanol
or intranasal administration of fentanyl, and has good
promise for clinical application.
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